Abstract
Administration of Chemotherapeutics, especially doxorubicin (DOX) and cyclophosphamide (CPS), is commonly associated with adverse effects such as myelosuppression and cardiotoxicity. At this time, few approved therapeutic options are currently available for the management of chemotherapy-associated cardiotoxicity. Thus, identification of novel therapeutics with potent cardioprotective properties and minimal adverse effects are pertinent in treating Doxorubicin and Cyclophosphamide-induced cardiotoxicity. Oroxylum indicum extract (OIE, Sabroxy®) is a natural product known to possess several beneficial biological functions including antioxidant, anti-inflammatory and cytoprotective effects. We therefore set to investigate the cardioprotective effects of OIE against Doxorubicin and Cyclophosphamide-induced cardiotoxicity and explore the potential cardioprotective mechanisms involved. Adult male mice were treated with DOX and CPS in combination, OIE alone, or a combination of OIE and DOX & CPS. Swimming test was performed to assess cardiac function. Markers of oxidative stress were assessed by levels of reactive oxygen species (ROS), nitrite, hydrogen peroxide, catalase, and glutathione content. The activity of interleukin converting enzyme and cyclooxygenase was determined as markers of inflammation. Mitochondrial function was assessed by measuring Complex-I activity. Apoptosis was assessed by Caspase-3 and protease activity. Mice treated with DOX and CPS exhibited reduced swim rate, increased oxidative stress, increased inflammation, and apoptosis in the heart tissue. These cardiotoxic effects were significantly reduced by co-administration of OIE. Furthermore, computational molecular docking studies revealed potential binding of DOX and CPS to tyrosine hydroxylase which validated our in vivo findings regarding the inhibition of tyrosine hydroxylase activity. Our current findings indicated that OIE counteracts Doxorubicin and Cyclophosphamide-induced cardiotoxicity—through inhibition of ROS-mediated apoptosis and by blocking the effect on tyrosine hydroxylase. Taken together, our findings suggested that OIE possesses cardioprotective effects to counteract potentially fatal cardiac complications associated with chemotherapy treatment.
Similar content being viewed by others
References
Dhesi, S., Chu, M. P., Blevins, G., Paterson, I., Larratt, L., Oudit, G. Y., & Kim, D. H. (2013). Cyclophosphamide-induced cardiomyopathy: A case report, review, and recommendations for management. Journal of Investigative Medicine High Impact Case Reports, 1(1), 2324709613480346. https://doi.org/10.1177/2324709613480346
Swain, S. M. (1999). Doxorubicin-induced cardiomyopathy. New England Journal of Medicine, 340(8), 654 (author reply 655)
Chen, Y., Jungsuwadee, P., Vore, M., Butterfield, D. A., & St Clair, D. K. (2007). Collateral damage in cancer chemotherapy: Oxidative stress in nontargeted tissues. Molecular Interventions, 7(3), 147–156. https://doi.org/10.1124/mi.7.3.6
Kluza, J. M., Marchetti, P., Gallego, M.-A., Lancel, S., Fournier, C., Loyens, A., et al. (2004). Mitochondrial proliferation during apoptosis induced by anticancer agents: Effects of doxorubicin and mitoxantrone on cancer and cardiac cells. Oncogene, 23(42), 7018–7030.
Vichaya, E. G., Chiu, G. S., Krukowski, K., Lacourt, T. E., Kavelaars, A., Dantzer, R., Heijnen, C. J., & Walker, A. K. (2015). Mechanisms of chemotherapy-induced behavioral toxicities. Frontiers in Neuroscience, 9, 131.
Chen, T., Shen, H.-M., Deng, Z.-Y., Yang, Z.-Z., Zhao, R.-L., Wang, L., et al. (2017). A herbal formula, SYKT, reverses doxorubicin-induced myelosuppression and cardiotoxicity by inhibiting ROS-mediated apoptosis. Molecular Medicine Reports, 15(4), 2057–2066. https://doi.org/10.3892/mmr.2017.6272
Menon, S., Lawrence, L., & Sivaram, V. P. (2019). Oroxylum indicum root bark extract prevents doxorubicin-induced cardiac damage by restoring redox balance. Journal of Ayurveda and Integrative Medicine, 10(3), 159–165. https://doi.org/10.1016/j.jaim.2017.06.007
Hajra, S., Basu, A., Singha Roy, S., Patra, A. R., & Bhattacharya, S. (2017). Attenuation of doxorubicin-induced cardiotoxicity and genotoxicity by an indole-based natural compound 3,3’-diindolylmethane (DIM) through activation of Nrf2/ARE signaling pathways and inhibiting apoptosis. Free Radical Research, 51(9–10), 812–827. https://doi.org/10.1080/10715762.2017.1381694
He, H., Luo, Y., Qiao, Y., Zhang, Z., Yin, D., Yao, J., et al. (2018). Curcumin attenuates doxorubicin-induced cardiotoxicity via suppressing oxidative stress and preventing mitochondrial dysfunction mediated by 14–3-3γ. Food & Function, 9(8), 4404–4418. https://doi.org/10.1039/c8fo00466h
Harminder, V. S., & Chaudhary, Y. (2011). A review on the taxonomy, ethnobotany, chemistry and pharmacology of Oroxylum indicum Vent. Indian Journal of Pharmaceutical Sciences, 73(5), 483–490. https://doi.org/10.4103/0250-474X.98981
Hemantha, H. P., Ramanujam, R., & Majeed, M. (2021). An unambiguous and practical synthesis of Oroxylin A: a commonly misidentified flavone. Natural Product Resarch, 35(9), 1413–1420. https://doi.org/10.1080/14786419.2019.1650359
Pondugula, S. R., Majrashi, M., Almaghrabi, M., Ramesh, S., Abbott, K. L., Govindarajulu, M., et al. (2021b). Oroxylum Indicum ameliorates chemotherapy induced cognitive impairment. PLoS ONE, 16(6), e0252522. https://doi.org/10.1371/journal.pone.0252522. eCollection 2021 using the current dose and dosage.
Pondugula, S. R., Salamat, J. M., Abbott, K. L., Flannery, P. C., Majrashi, M., Almaghrabi, M., et al. (2021c) Oroxylum indicum extract, at a physiologically relevant dosage, does not induce hepatotoxicity in C57BL/6J mice. Natural Product Communications, 16 (5), 1934578X211016966.
Muralikrishnan, D., & Mohanakumar, K. (1998). Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced neurotoxicity in mice1. The FASEB journal, 12(10), 905–912.
Grippo, A. J., Moffitt, J. A., Sgoifo, A., Jepson, A. J., Bates, S. L., Chandler, D. L., et al. (2012). The integration of depressive behaviors and cardiac dysfunction during an operational measure of depression: Investigating the role of negative social experiences in an animal model. Psychosomatic Medicine, 74(6), 612–619. https://doi.org/10.1097/PSY.0b013e31825ca8e5
Ramesh, S., Bhattacharya, D., Majrashi, M., Morgan, M., Prabhakar Clement, T., & Dhanasekaran, M. (2018). Evaluation of behavioral parameters, hematological markers, liver and kidney functions in rodents exposed to Deepwater Horizon crude oil and Corexit. Life Sciences, 199, 34–40. https://doi.org/10.1016/j.lfs.2018.02.028
Majrashi, M., Almaghrabi, M., Fadan, M., Fujihashi, A., Lee, W., Deruiter, J., Clark, C. R., & Dhanasekaran, M. (2018). Dopaminergic neurotoxic effects of 3-TFMPP derivatives. Life Sciences, 209, 357–369.
Pondugula, S. R., Majrashi, M., Almaghrabi, M., Abbott, K., Govindarajulu, M., Ramesh, S. et al. (2020). Predictable hematological markers associated with cognitive decline in valid rodent models of cognitive impairment. Toxicology Mechanisms and Methods, 30(6), 454–461. https://doi.org/10.1080/15376516.2020.1760984
Katz, D. P., Majrashi, M., Ramesh, S., Govindarajulu, M., Bhattacharya, D., Bhattacharya, S, Shlghom, A., Bradford, C., Suppiramaniam, V., Deruiter, J., Clark, C. R., & Dhanasekaran, M. (2018). Comparing the dopaminergic neurotoxic effects of benzylpiperazine and benzoylpiperazine. Toxicology Mechanisms and Methods, 28(3), 177–186. https://doi.org/10.1080/15376516.2017.1376024
Al Saqr, A., Majrashi, M., Alrbyawi, H., Govindarajulu, M., Fujihashi, A., Gottumukkala, S., Poudel, I., Arnold, R. D., Babu, R. J., & Dhanasekaran, M. (2020). Elucidating the anti-melanoma effect and mechanisms of Hispolon. Life Sciences, 256, 117702. https://doi.org/10.1016/j.lfs.2020.117702
Majrashi, M., Fujihashi, A., Almaghrabi, M., Fadan, M., Fahoury, E., Ramesh, S., Govindarajulu, M., Beamon, H., Bradford, C. N., Bolden-Tiller, O., & Dhanasekaran, M. (2020). Augmented oxidative stress and reduced mitochondrial function in ageing goat testis. Veterinary Medicine and Science, 6, 766–774.
Ahuja, M., Buabeid, M., Abdel-Rahman, E., Majrashi, M., Parameshwaran, K., Amin, R., et al. (2017). Immunological alteration & toxic molecular inductions leading to cognitive impairment & neurotoxicity in transgenic mouse model of Alzheimer’s disease. Life Sciences, 177, 49–59. https://doi.org/10.1016/j.lfs.2017.03.004
Vermeer, L. M., Higgins, C. A., Roman, D. L., & Doorn, J. A. (2013). Real-time monitoring of tyrosine hydroxylase activity using a plate reader assay. Analytical Biochemistry, 432(1), 11–15. https://doi.org/10.1016/j.ab.2012.09.005
Daubner, S. C., Le, T., & Wang, S. (2011). Tyrosine hydroxylase and regulation of dopamine synthesis. Archives of Biochemistry and Biophysics, 508(1), 1–12. https://doi.org/10.1016/j.abb.2010.12.017
Vrana, K. E., Walker, S. J., Rucker, P., & Liu, X. (1994). A carboxyl terminal leucine zipper is required for tyrosine hydroxylase tetramer formation. Journal of Neurochemistry, 63(6), 2014–2020. https://doi.org/10.1046/j.1471-4159.1994.63062014.x
Joerger, M., Huitema, A. D. R., Richel, D. J., Dittrich, C., Pavlidis, N., Briasoulis, E., et al. (2007). Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients. Clinical Pharmacokinetics, 46(12), 1051–1068. https://doi.org/10.2165/00003088-200746120-00005
Ma, B., Yeo, W., Hui, P., Ho, W. M., & Johnson, P. J. (2002). Acute toxicity of adjuvant doxorubicin and cyclophosphamide for early breast cancer—A retrospective review of Chinese patients and comparison with an historic Western series. Radiotherapy and Oncology, 62(2), 185–189. https://doi.org/10.1016/s0167-8140(02)00003-8
Tsutani, Y., Saeki, T., Aogi, K., Ohsumi, S., & Takashima, S. (2005). Toxicity of doxorubicin and cyclophosphamide (60 mg/600 mg/m2) in adjuvant chemotherapy for breast cancer. Gan to Kagaku Ryoho, 32(6), 809–813.
Begum, M. M., Islam, A., Begum, R., Uddin, M. S., Rahman, M. S., Alam, S., Akter, W., Das, M., Rahman, M. S., & Imon, A. (2019). Ethnopharmacological inspections of organic extract of Oroxylum indicum in rat models: A promising natural gift. Evidence-Based Complementary and Alternative Medicine: ECAM, 2019, 1562038.
Das, B. K., Al-Amin, M. M., Russel, S. M., Kabir, S., Bhattacherjee, R., & Hannan, J. M. (2014). Phytochemical screening and evaluation of analgesic activity of Oroxylum indicum. Indian Journal of Pharmaceutical Sciences, 76, 571–575.
Karnati, M., Chandra, R. H., Veeresham, C., & Kishan, B. (2013). Anti-arthritic activity of root bark of Oroxylum indicum (L.) vent against adjuvant-induced arthritis. Pharmacognosy Research, 5, 121–128.
Pondugula, S. R., Salamat, J. M., Abbott, K. L., Flannery, P. C., Majrashi, M., Almaghrabi, M., et al. (2021a). Oroxylum indicum extract, at a physiologically relevant dosage, does not induce hepatotoxicity in C57BL/6J mice. Natural Product Communications, 16(5), 1934578X211016966.
Reduan, M. F. H., Hamid, F. F. A., Nordin, M. L., Shaari, R., Hamdan, R. H., Chung, E. L. T., Peng, T. L., Kamaruzaman, I. N. A., & Noralidin, N. (2020). Acute oral toxicity study of ethanol extract of Oroxylum indicum leaf in mice. The Thai Journal of Veterinary Medicine, 50, 573–581.
Deori, K., & Yadav, A. K. (2016). Anthelmintic effects of Oroxylum indicum stem bark extract on juvenile and adult stages of Hymenolepis diminuta (Cestoda), an in vitro and in vivo study. Parasitology Research, 115, 1275–1285.
Menon, et al. (2017). Oroxylum indicum root bark extract prevents doxorubicin-induced cardiac damage by restoring redox balance. https://doi.org/10.1016/j.jaim.2017.06.007
Mahoney, S. E., Davis, J. M., Murphy, E. A., McClellan, J. L., Gordon, B., & Pena, M. M. (2013). Effects of 5-fluorouracil chemotherapy on fatigue: Role of MCP-1. Brain, Behavior, and Immunity, 27, 155–161. https://doi.org/10.1016/j.bbi.2012.10.012
Dougherty, J. P., Springer, D. A., Cullen, M. J., & Gershengorn, M. C. (2019). Evaluation of the effects of chemotherapy-induced fatigue and pharmacological interventions in multiple mouse behavioral assays. Behavioural Brain Research, 360, 255–261. https://doi.org/10.1016/j.bbr.2018.12.011
Wang, H.-W., Ahmad, M., Jadayel, R., Najjar, F., Lagace, D., & Leenen, F. H. H. (2019). Inhibition of inflammation by minocycline improves heart failure and depression-like behaviour in rats after myocardial infarction. PLoS ONE, 14(6), e0217437–e0217437. https://doi.org/10.1371/journal.pone.0217437
Songbo, M., Lang, H., Xinyong, C., Bin, X., Ping, Z., & Liang, S. (2019). Oxidative stress injury in doxorubicin-induced cardiotoxicity. Toxicology Letters, 307, 41–48. https://doi.org/10.1016/j.toxlet.2019.02.013
Zhang, X., Hu, C., Kong, C.-Y., Song, P., Wu, H.-M., Xu, S.-C., et al. (2020). FNDC5 alleviates oxidative stress and cardiomyocyte apoptosis in doxorubicin-induced cardiotoxicity via activating AKT. Cell Death & Differentiation, 27(2), 540–555. https://doi.org/10.1038/s41418-019-0372-z
Syed, F. M., Hahn, H. S., Odley, A., Guo, Y., Vallejo, J. G., Lynch, R. A., et al. (2005). Proapoptotic effects of caspase-1/interleukin-converting enzyme dominate in myocardial ischemia. Circulation Research, 96(10), 1103–1109. https://doi.org/10.1161/01.RES.0000166925.45995.ed
Bakhle, Y. S. (2001). COX-2 and cancer: A new approach to an old problem. British Journal of Pharmacology, 134(6), 1137–1150. https://doi.org/10.1038/sj.bjp.0704365
Ricci, M. S., & Zong, W.-X. (2006). Chemotherapeutic approaches for targeting cell death pathways. The Oncologist, 11(4), 342–357. https://doi.org/10.1634/theoncologist.11-4-342
Urra, F. A., Muñoz, F., Lovy, A., & Cárdenas, C. (2017). The mitochondrial Complex(I)ty of cancer. Frontiers in Oncology, 7, 118–118. https://doi.org/10.3389/fonc.2017.00118
Mladěnka, P., Applová, L., Patočka, J., Costa, V. M., Remiao, F., Pourová, J., et al. (2018). Comprehensive review of cardiovascular toxicity of drugs and related agents. Medicinal Research Reviews, 38(4), 1332–1403. https://doi.org/10.1002/med.21476
Author information
Authors and Affiliations
Corresponding authors
Additional information
Handling editor: Jianyong Ma
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Pondugula, S.R., Harshan, A., Ramesh, S. et al. Cardioprotective Effects of Oroxylum indicum Extract Against Doxorubicin and Cyclophosphamide-Induced Cardiotoxicity. Cardiovasc Toxicol 22, 67–77 (2022). https://doi.org/10.1007/s12012-021-09701-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12012-021-09701-x